|
¹ÙÀÌ¿ÀÀÌÁî |
¹ÙÀÌ¿ÀÀÌÁî AptaSign ÀÓ»óÆÀ ¸ðÁý
¼¿ï ±¸·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
10³â¡è |
ä¿ë½Ã |
05.11 |
|
|
¿À½ºÅÛÀÓÇöõÆ® |
¿À½ºÅÛÀÓÇöõÆ® Ä¡°ú ¿µ»óÀÇ·á±â±â À籸¼º ¾Ë°í¸®Áò °³¹ßÀÚ
¼¿ï ±Ýõ±¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
10³â¡è |
ä¿ë½Ã |
03.18 |
|
|
(ÁÖ)¹ÙÀÌ¿À¸®´õ½º |
(ÁÖ)¹ÙÀÌ¿À¸®´õ½º Àü·«±âȹ½Ç BDÆÀ °æ·ÂÁ÷ ä¿ë
°æ±â ¿ëÀνà | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
8³â¡è |
ä¿ë½Ã |
03.04 |
|
|
(ÁÖ)°í¹ÙÀÌ¿À·¦ |
[ÁÖ4.5ÀÏ]ÀÓ»óÆÀ ÆÀÀå ä¿ë
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
8³â¡è |
05.12 |
04.26 |
|
|
PPD Korea |
[PPD] ä¿ë°ø°í - Principal Regulatory Affairs Specialist
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
8³â¡è |
ä¿ë½Ã |
03.03 |
|
|
±¹Á¦¹é½Å¿¬±¸¼Ò |
Research Assistant (PER) ¸ðÁý
¼¿ï °ü¾Ç±¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
7³â¡è |
ä¿ë½Ã |
07.04 |
|
|
(ÁÖ)È޿½º |
È޿½º·¦ ¹ÙÀÌ¿À»ç¾÷ºÎ BDÆÀ °æ·ÂÁ÷ ¸ðÁý
°æ±â ¼º³²½Ã ¼öÁ¤±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
7³â¡è |
05.12 |
05.03 |
|
|
±¹Á¦¹é½Å¿¬±¸¼Ò |
Associate Research Scientist (PER) ¸ðÁý
¼¿ï °ü¾Ç±¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
7³â¡è |
ä¿ë½Ã |
07.04 |
|
|
Çѱ¹º¤Å©¸¸ÄðÅÍ |
[Çѱ¹º¤Å©¸¸ÄðÅÍ] RA SR. SPECIALIST °æ·ÂÁ÷ ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
5³â¡è |
»ó½Ãä¿ë |
04.12 |
|
|
Çѱ¹½ºÆ®¶óÀÌÄ¿(ÁÖ) |
Business Development Manager
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
5³â¡è |
ä¿ë½Ã |
01.12 |
|
|
¾Ëº¸Á¨ÄÚ¸®¾Æ |
BD In-License Specialist ä¿ë
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
5³â¡è |
ä¿ë½Ã |
01.16 |
|
|
½ÎÀÌÁ¨ÄÚ¸®¾Æ(ÁÖ) |
[¿Ü±¹°è Á¦¾à] RA Assistant Manager / Manager (´ë¸®/°úÀå
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
5³â¡è |
ä¿ë½Ã |
11.24 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Clinical Project Leader
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
5³â¡è |
ä¿ë½Ã |
08.29 |
|
|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
SCºÎ¼ RA °æ·Â ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
5³â¡è |
ä¿ë½Ã |
12.05 |
|
|
¿òÆ®(umt) |
ÀÓ»ó BD (Business Development) °æ·ÂÁ÷ ä¿ë
¼¿ï ±¸·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
5³â¡è |
ä¿ë½Ã |
04.30 |
|